Skip to main content
. Author manuscript; available in PMC: 2021 Oct 6.
Published in final edited form as: Expert Opin Ther Targets. 2020 Oct 6;24(9):899–914. doi: 10.1080/14728222.2020.1790528

Figure 2. Concentric plot showing the recent evolution of drugs and strategies for HR-NB.

Figure 2.

Inner circle: Partial list (from 506 current clinical trials) of targeted drugs, modalities, and/or their combination in current clinical evaluation in Phase I, II, and III trials. Outer circle: Partial list of potential and promising targeted (discussed in the text) developed or repurposed drugs (e. g., inhibitors, miRs, antibodies, peptides, gene silencing, clinical drugs) that were validated in preclinical settings, alone and/or in combination with conventional chemotherapy for HR-NB. Combination strategies revealed that these candidates integrated well with drugs in current clinical therapy, with a synergistic effect in the HR-NB setting.